Agenus Inc. Grants CEO Performance-Based Stock Options

What Happened
Agenus Inc. announced on Aug. 10, 2026 that its Compensation Committee approved a special, one-time award of 1,971,500 performance-based stock options to Chairman and CEO Garo H. Armen under the company’s 2019 Equity Incentive Plan. The options have a 10-year term and an exercise price of $7.78 per share (the same price used for management grants on Aug. 5, 2026), a price Dr. Armen requested even though it exceeded the Aug. 10, 2026 closing market price. The Committee used independent advice from Aon Talent Solutions when structuring the award.

Key Details

• Grant size: 1,971,500 stock options; 10-year term.
• Exercise price: $7.78 per share (set at Dr. Armen’s request; higher than the Aug. 10 close).
• Vesting: Options split into five equal tranches; each tranche vests only if the stock trades at or above 3x, 4x, 5x, 6x and 8x the $7.78 measurement price, respectively, sustained for 30 consecutive calendar days within a five-year performance period. Each tranche also requires a minimum three-year service requirement.
• Termination and other terms: Unvested options are forfeited on termination for any reason (including retirement or change in control); no automatic acceleration except the Committee may, in its discretion, vest previously earned tranches in case of death or disability. Shares issued on exercise are generally subject to a one-year post-exercise holding requirement (except as needed for tax withholding). The award is subject to the company’s clawback policy.

Why It Matters
This award ties a large portion of the CEO’s potential compensation to substantial future increases in Agenus’s stock price (3x to 8x of $7.78), aligning pay with long‑term stock performance rather than guaranteed cash. Because the exercise price was set above the market close on Aug. 10, the options start with a premium that requires meaningful share-price appreciation before value is realized. Investors should watch future filings for related compensation expense, any changes to outstanding share count if options vest and are exercised, and disclosures about whether performance hurdles are met.